[
    [
        {
            "time": "2018-01-31",
            "original_text": "Vertex Beats Views, Closes In On Cystic Fibrosis Treatments",
            "features": {
                "keywords": [
                    "Vertex",
                    "Beats",
                    "Cystic Fibrosis",
                    "Treatments"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Vertex Beats Views, Closes In On Cystic Fibrosis Treatments",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "Lilly Issues Beat-And-Raise But Dives Alongside Other Drug Stocks",
            "features": {
                "keywords": [
                    "Lilly",
                    "Beat-And-Raise",
                    "Dives",
                    "Drug Stocks"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly Issues Beat-And-Raise But Dives Alongside Other Drug Stocks",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-31",
            "original_text": "Despite Tax-Cut, Pfizer Inc. Remains a Slow-Growth Company",
            "features": {
                "keywords": [
                    "Tax-Cut",
                    "Pfizer",
                    "Slow-Growth"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Despite Tax-Cut, Pfizer Inc. Remains a Slow-Growth Company",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance",
            "features": {
                "keywords": [
                    "Lilly",
                    "Q4 Earnings",
                    "Raises",
                    "2018 EPS Guidance"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "AbbVie Is Ruining Pharma Earnings Season",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Ruining",
                    "Pharma",
                    "Earnings Season"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Is Ruining Pharma Earnings Season",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "Bank of America",
                    "Citigroup",
                    "AbbVie",
                    "3M",
                    "Starbucks",
                    "Halliburton"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "financials",
                    "healthcare",
                    "consumer goods",
                    "industrials"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View",
            "features": {
                "keywords": [
                    "Anthem",
                    "Q4 Earnings",
                    "Revenues",
                    "'18 View"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "insurance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "Johnson & Johnson’s Medical Devices Business in 4Q17",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Medical Devices",
                    "4Q17"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Johnson & Johnson’s Medical Devices Business in 4Q17",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "The Best Arthritis Drug/Treatment Stocks on the Market Right Now",
            "features": {
                "keywords": [
                    "Arthritis",
                    "Drug/Treatment",
                    "Stocks"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Best Arthritis Drug/Treatment Stocks on the Market Right Now",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-31",
            "original_text": "Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX",
            "features": {
                "keywords": [
                    "Drug/Biotech Stocks",
                    "Q4 Earnings",
                    "LLY",
                    "VRTX"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]